ERBB2 and triple-negative breast carcinoma: Depletion of CHD4 significantly decreases cell proliferation and migration in HER2-positive and triple-negative breast cancer cell lines, leading to a reduction in tumor mass in luminal B and HER2-ortholog-activated triple-negative PDX and transgenic mouse models (D'Alesio et al., 2016; D'Alesio et al., 2019).